Alembic Pharma surges 20% on USFDA nod for anti-depression drug

NEW DELHI: Shares of Alembic Pharma hit upper circuit of 20 per cent on Monday after the company received USFDA's nod for bupropion hydrochloride tablets. The drug is used for the treatment of major depressive disorder.

"The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for bupropion hydrochloride tablets," Alembic Pharmaceuticals said in a BSE filing.

The tablets USP, 75 mg and 100 mg, have an estimated market size of $37 million for 12 months ending December 2017, according to IMS.


Alembic now has a total of 72 ANDA approvals (64 final approvals and 8 tentative approvals) from USFDA. ANDA stands for Abbreviated New Drug Application, the BSE filing said.

Alembic manufactures and markets generic pharmaceutical products.

At 01:35 pm, shares of the company were trading at Rs 521.80 apiece on BSE.